Bioline Launches New JetSeq DNA Quantification Kits
March 27 2017 - 10:50AM
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO) today announced the further
expansion of the JetSeq™ portfolio for Next Generation Sequencing
(NGS) sample preparation.
The new JetSeq™ Library Quantification Kit is a
qPCR-based assay that provides fast, accurate and sensitive
quantification of adaptor-ligated DNA fragments during the
preparation of Illumina compatible NGS libraries. The JetSeq™
Library Quantification Kit relies on SYBR®1 Green I for
detection and contains all of the components required for library
quantification, including dilution buffer, P5 and P7 adapter
primers and six pre-diluted DNA standards to minimize pipetting,
reduce variability and thereby increase reproducibility. The kit
has sufficient standards to quantify eighteen libraries on
individual plates or up to seventy-six libraries when multiple
libraries are quantified on the same plate.
Marco Calzavara, President of Bioline commented,
“The release of the new JetSeq™ Library Quantification Kit
compliments the JetSeq™ Library preparation kits that Bioline
launched last month, moving us even further into the NGS space. The
kit builds on our extensive knowledge in qPCR, providing a fast,
sensitive and reliable solution to determine library
concentrations, giving customers confidence in the cluster density
loaded on Illumina sequencing platforms.”
Richard L. Eberly, President, Chief Commercial
Officer, stated, “We are pleased to announce the release of the new
JetSeq™ Library Quantification Kit; this is an important addition
to our ever-increasing portfolio of NGS products and gives our life
science customers greater confidence in the quantification of their
sequencing libraries. The further development of the JetSeq™ family
shows our commitment, not just to the continued development and
expansion of products from Bioline, but also to our customers,
giving them a greater support around this fast-growing market.”
About Meridian Bioscience,
Inc.Meridian is a fully integrated life science company
that develops, manufactures, markets and distributes a broad range
of innovative diagnostic test kits, rare reagents, specialty
biologicals and components. Utilizing a variety of methods, our
diagnostic tests provide accuracy, simplicity and speed in the
early diagnosis and treatment of common medical conditions, such as
infections and lead poisoning. Meridian’s diagnostic products are
used outside of the human body and require little or no special
equipment. The Company's diagnostic products are designed to
enhance patient well-being while reducing the total outcome costs
of health care. Meridian has strong market positions in the areas
of gastrointestinal and upper respiratory infections and blood lead
level testing. In addition, Meridian is a supplier of rare
reagents, specialty biologicals and components used by
organizations in the life science and agribio industries engaged in
research and by companies as components in the manufacture of
diagnostics. The Company markets its products and technologies to
hospitals, reference laboratories, research centers, diagnostics
manufacturers and agribio companies in more than 70 countries
around the world. The Company’s shares are traded on the NASDAQ
Global Select Market, symbol VIVO. Meridian's website address is
www.meridianbioscience.com.
FOR ADDITIONAL INFORMATION:For more information
about Bioline, please visit http://www.bioline.com.
1 SYBR is a registered trademark of Thermo Fisher
Scientific.
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Sep 2023 to Sep 2024